The influence of non-cancer-related risk factors on the development of cancer-related lymphedema: a rapid review.

IF 2.8 4区 医学 Q2 ONCOLOGY Medical Oncology Pub Date : 2024-10-14 DOI:10.1007/s12032-024-02474-7
Nicole L Stout, McKinzey Dierkes, Jill M Oliveri, Stanley Rockson, Electra D Paskett
{"title":"The influence of non-cancer-related risk factors on the development of cancer-related lymphedema: a rapid review.","authors":"Nicole L Stout, McKinzey Dierkes, Jill M Oliveri, Stanley Rockson, Electra D Paskett","doi":"10.1007/s12032-024-02474-7","DOIUrl":null,"url":null,"abstract":"<p><p>Extensive research supports an evidence-base for cancer treatment-related risk factors, including extent of lymph node dissection and use of radiotherapy, as contributing to secondary lymphedema. Additionally, comorbidities, such as higher body mass index, and vascular-related conditions are identified to further augment risk. While social determinants of health (SDOH) and socioeconomic factors are widely regarded as influencing an individual's healthcare outcomes, including cancer risk and survival, these factors have not been explored as risk factors for developing secondary lymphedema. A rapid literature review explored the current evidence for SDOH as risk factors for lymphedema. Studies that were published over the last 10 years and that specifically analyzed social factors as variables associated with lymphedema were included. Studies that only characterized the social determinants of the study population were not included. Forty-nine studies were identified through a rapid literature review, and 13 studies that expressly analyzed social determinants as risk factors for secondary lymphedema were reviewed and extracted. All studies were conducted in patients with breast cancer-related lymphedema. Social risk factors included race, educational level, insurance type, and income level. These are consistent with the socioeconomic inequalities related to cancer survival. SDOH may influence the risk of developing cancer treatment-related health conditions like secondary lymphedema. Research trials studying cancer treatment-related conditions should collect consistent and robust data across social, behavioral, environmental, and economic domains and should analyze these variables to understand their contribution to study endpoints. Risk prediction modeling could be a future pathway to better incorporate social determinants, along with medical and co-morbidity data, to holistically understand lymphedema risk.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02474-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Extensive research supports an evidence-base for cancer treatment-related risk factors, including extent of lymph node dissection and use of radiotherapy, as contributing to secondary lymphedema. Additionally, comorbidities, such as higher body mass index, and vascular-related conditions are identified to further augment risk. While social determinants of health (SDOH) and socioeconomic factors are widely regarded as influencing an individual's healthcare outcomes, including cancer risk and survival, these factors have not been explored as risk factors for developing secondary lymphedema. A rapid literature review explored the current evidence for SDOH as risk factors for lymphedema. Studies that were published over the last 10 years and that specifically analyzed social factors as variables associated with lymphedema were included. Studies that only characterized the social determinants of the study population were not included. Forty-nine studies were identified through a rapid literature review, and 13 studies that expressly analyzed social determinants as risk factors for secondary lymphedema were reviewed and extracted. All studies were conducted in patients with breast cancer-related lymphedema. Social risk factors included race, educational level, insurance type, and income level. These are consistent with the socioeconomic inequalities related to cancer survival. SDOH may influence the risk of developing cancer treatment-related health conditions like secondary lymphedema. Research trials studying cancer treatment-related conditions should collect consistent and robust data across social, behavioral, environmental, and economic domains and should analyze these variables to understand their contribution to study endpoints. Risk prediction modeling could be a future pathway to better incorporate social determinants, along with medical and co-morbidity data, to holistically understand lymphedema risk.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非癌症相关风险因素对癌症相关淋巴水肿发展的影响:快速综述。
大量研究证明,与癌症治疗相关的风险因素(包括淋巴结清扫范围和放疗的使用)是导致继发性淋巴水肿的证据基础。此外,合并症(如较高的体重指数)和血管相关疾病也被认为会进一步增加风险。虽然人们普遍认为健康的社会决定因素(SDOH)和社会经济因素会影响个人的医疗结果,包括癌症风险和存活率,但这些因素尚未被视为继发性淋巴水肿的风险因素。一项快速文献综述探讨了 SDOH 作为淋巴水肿风险因素的现有证据。其中包括过去 10 年间发表的、专门分析社会因素作为淋巴水肿相关变量的研究。仅描述研究人群社会决定因素的研究未被纳入。通过快速文献综述确定了 49 项研究,并审查和提取了 13 项明确分析社会决定因素作为继发性淋巴水肿风险因素的研究。所有研究均针对乳腺癌相关淋巴水肿患者。社会风险因素包括种族、教育水平、保险类型和收入水平。这些因素与癌症存活率相关的社会经济不平等现象一致。SDOH 可能会影响继发性淋巴水肿等癌症治疗相关健康状况的发病风险。研究癌症治疗相关病症的试验应收集社会、行为、环境和经济领域的一致且可靠的数据,并对这些变量进行分析,以了解它们对研究终点的影响。风险预测模型可能是未来更好地将社会决定因素与医疗和并发症数据结合起来以全面了解淋巴水肿风险的一个途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical Oncology
Medical Oncology 医学-肿瘤学
CiteScore
4.20
自引率
2.90%
发文量
259
审稿时长
1.4 months
期刊介绍: Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
期刊最新文献
ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma. The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology. CAP superfamily proteins in human: a new target for cancer therapy. Letter to the editor on "Targeted gene therapy for cancer: the impact of microRNA multipotentiality". Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1